CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 51 enrolled
Drug / intervention
Bupivacaine +1 moredrug
Likely dose
Bupivacaine 30mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02052557
NCT02052557Phase 4Completed

The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery

Des Moines University·interventional·Posted Feb 3, 2014·Updated Jan 8, 2021

In Brief

A Phase 4 clinical trial evaluating Bupivacaine and Bupivacaine liposome suspension for Post-operative Pain and 2 related conditions. Completed, enrolled 51 participants across 1 site.

Detailed Summary

The purpose of the study is to evaluate the effect of Exparel on pain control and patient outcome after colon resection. The investigators will evaluate the clinical course of the patients who receive exparel as compared to the patients who do not receive exparel. Exparel is a 72 hour bupivacaine which is slowly released from lysosomes over the course of three days. A long acting local anesthetic should provide better pain control than conventional bupivacaine which has a 3.5 hour half-life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2014
Enrollment StartFeb 1, 2013
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.4 years ago

Interventions

Bupivacainedrug

30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR

Bupivacaine liposome suspensiondrug

30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR